Barbara Gayle Duncan - Insider Trading & Ownership

Location
C/O Intercept Pharmaceuticals, Inc., 18 Desbrosses Street, New York, NY
Summary
The estimated net worth of Barbara Gayle Duncan is at least $1.49M dollars as of June 24, 2025. Barbara Gayle Duncan is the Director of HALOZYME THERAPEUTICS, INC. and owns shares of HALOZYME THERAPEUTICS, INC. (HALO) stock worth about $1.2M. Barbara Gayle Duncan is the Director of Atea Pharmaceuticals, Inc. and owns shares of Atea Pharmaceuticals, Inc. (AVIR) stock worth about $288K.
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for Barbara Gayle Duncan
All Insider Reports
All Insider Reports

Ownership of Barbara Gayle Duncan

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
HALO HALOZYME THERAPEUTICS, INC. Director $1.2M May 1, 2025
AVIR Atea Pharmaceuticals, Inc. Director $288K Jun 20, 2025
ADAP Adaptimmune Therapeutics PLC Director Jul 1, 2022
FUSN Fusion Pharmaceuticals Inc. Director Jun 4, 2024
JNCE Jounce Therapeutics, Inc. Director May 3, 2023
OVID Ovid Therapeutics Inc. Director Feb 20, 2025

Insider Transactions Reported by Barbara Gayle Duncan:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.